RoslinCT, a global contract development and manufacturing organization (CDMO) specializing in advanced cell therapies, and ...
MedPage Today on MSN
GLP-1 Drug Market Changes; Wegovy Pill Hits Shelves; Hypercortisolism Drug Rejected
And in a phase III trial win, Foresee Pharmaceuticals said its long-acting gonadotropin-releasing hormone agonist leuprolide ...
Ultragenyx Pharmaceutical and Mereo BioPharma Group saw their shares plummet after ringing out 2025 by announcing the failures of their brittle bone disease candidate setrusumab (UX143) in a pair of ...
Topline data were announced from two phase 3 studies evaluating setrusumab in patients with osteogenesis imperfecta.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback